European Heart Journal Advance Access originally published online on July 6, 2006
European Heart Journal 2006 27(15):1841-1846; doi:10.1093/eurheartj/ehl135
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation
1 Department of Cardiology, the Second Affiliated Hospital of Chongqing University of Medical Sciences, Chongqing 400010, China
2 Department of Medicine/Cardiology, The Johns Hopkins University School of Medicine, The Johns Hopkins Hospital/Carnegie 592, 600 N. Wolfe Street, Baltimore, MD 21287, USA
3 Department of Medicine and Therapeutics, The Chinese University of Hongkong, Hongkong, China
Received 3 January 2006; revised 15 May 2006; accepted 15 June 2006; online publish-ahead-of-print 6 July 2006.
* Corresponding authors. Tel: +86 23 63777035; fax: +86 23 63822815. E-mail address: yinyuehui63{at}yahoo.com.cn(Y. Yin); jdong4{at}jhmi.edu( J. Dong)
Aims The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF.
Methods and results One-hundred and seventy-seven patients with lone paroxysmal AF were randomly assigned to three treatment groups: group 1 received low-dose amiodarone alone, group 2 received low-dose amiodarone plus losartan, and group 3 received low-dose amiodarone plus perindopril. Left atrial diameter was measured with transthoracic echocardiogram at baseline and 6, 12, 18, and 24 months after randomization. The primary endpoint was the incidence of AF documented by 12-lead ECG or Holter after 14 days and within 24 months after randomization. The primary endpoint was reached in 24 patients (41%) in group 1, 11 (19%) in group 2, and 14 (24%) in group 3 (P = 0.02). The Kaplan–Meier survival analysis demonstrated a significant reduction in AF recurrence in group 2 (P = 0.006, log-rank test) as well as in group 3 (P = 0.04, log-rank test) when compared with group 1. No difference in the AF recurrence-free survival was found between group 2 and group 3. After 24 months follow-up, the left atrial diameter in group 2 and group 3 was significantly smaller than that in group 1 (36 ± 2.3 and 35 ± 2.4 vs. 38 ± 2.4 mm, P < 0.001 for both comparisons).
Conclusion The results of this study suggest that the combination of perindopril or losartan with low-dose amiodarone is more effective than low-dose amiodarone alone for the prevention of AF recurrence in patients with lone paroxysmal AF. Adding losartan or perindopril to amiodarone can inhibit left atrial enlargement in this group of patients.
Key Words: Atrial fibrillation • Amiodarone • Losartan • Perindopril
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. K. Kim, H.-N. Pak, J. H. Park, K. J. Ko, J. S. Lee, J. I. Choi, D. H. Choi, and Y.-H. Kim Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion Europace, October 26, 2009; (2009) eup321v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zhang Atrial fibrillation in mainland China: epidemiology and current management Heart, July 1, 2009; 95(13): 1052 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ozben, M. Sumerkan, A. M. Tanrikulu, N. Papila-Topal, A. S. Fak, and A. Toprak Perindopril decreases P wave dispersion in patients with stage 1 hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 85 - 90. [Abstract] [PDF]
|
|
|
|
 |
|
 The GISSI-AF Investigators Valsartan for Prevention of Recurrent Atrial Fibrillation N. Engl. J. Med., April 16, 2009; 360(16): 1606 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gillis Angiotensin-Receptor Blockers for Prevention of Atrial Fibrillation -- A Matter of Timing or Target? N. Engl. J. Med., April 16, 2009; 360(16): 1669 - 1671. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ahmed, H. J. G. M. Crijns, and I. C. Van Gelder Treatment With Amiodarone to Prevent Atrial Fibrillation--Reply JAMA, March 11, 2009; 301(10): 1020 - 1020. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Serra and M. Bendersky Review: Atrial fibrillation and renin-angiotensin system Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 215 - 223. [Abstract] [PDF]
|
|
|
|
|
|
F. G. Cosio, E. Aliot, G. L. Botto, H. Heidbuchel, C. J. Geller, P. Kirchhof, J.-C. De Haro, R. Frank, J. P. Villacastin, J. Vijgen, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode Europace, January 1, 2008; 10(1): 21 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Van Gelder Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue Cardiovasc Res, April 1, 2007; 74(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yin Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation: reply Eur. Heart J., February 1, 2007; 28(3): 381 - 381. [Full Text] [PDF]
|
|
|
|
|
|
T. Liu and G. Li Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: potential benefits for the prevention of atrial fibrillation Eur. Heart J., October 1, 2006; 27(19): 2370 - 2371. [Full Text] [PDF]
|
|